Skip to content

Urinary and Anorectal Functional Disorders and Their Impact on CF Adults (PerineoMucoRMO)

Assessment of the Prevalence and Severity of Urinary and Ano-rectal Functional Disorders and Their Impact on Quality of Life and Sexuality on CF Adults of the North-West CF Network

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT02894619
Acronym
PerineoMuco
Enrollment
180
Registered
2016-09-09
Start date
2017-01-31
Completion date
2018-06-30
Last updated
2021-05-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cystic Fibrosis

Keywords

urinary incontinence, anal incontinence, sexuality, quality of life

Brief summary

This observational study evaluates prevalence of functional perinea disorders (stress urinary incontinence, overactive bladder syndrome, dysuria, anal incontinence) on CF adults patients of the North-West CF Network. Its aims are to measure the severity of urinary and anorectal symptoms ; assess their impact on patients' quality of life, sexuality, care and social life and relationships ; identify the medical and demographic factors associated with the severity of urinary and anorectal disorders and their impact and determine the relationship between the severity of these disorders, various repercussions, and risk factors.

Detailed description

Urine and/or anal leakage are more frequent and troublesome for CF patients: leaks occur during efforts or laugh like in other people, but also when coughing or sneezing, which are amplified during periods of exacerbation and with the degradation of the pulmonary condition. In addition, fear of leakage can disrupt medical care: discomfort during physiotherapy, pulmonary function test. Urinary and anorectal functional disorders are therefore not only a factor degrading the quality of life but also a risk factor for worsening bronchial obstruction, patients limiting their cough and / or their care to avoid episodes of leakage. Given the lack literature data, investigators wanted to explore these areas. Validated and specific questionnaires will be self and anonymously administered to adult patients (n=175). The time requested to fill the forms is estimated to 1H. Questionnaires about sexual health are optional. Prospects considered, depending on the results, are: * Extension to the adolescent population (14 and over); * National extension; * Systematic proposal of a screening and an appropriate management of pelvic floor functional disorders, depending on influent characteristics (age, gender ...): multidisciplinary working group to develop guidelines and specific tools for professional training and / or patient education; * Implementation of a comparative study of interventions.

Interventions

None listed

Sponsors

Vaincre la Mucoviscidose
CollaboratorOTHER
University Hospital, Brest
CollaboratorOTHER
Fondation Ildys
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Men and women 18 years and over * Cystic fibrosis confirmed by sweat test or genetic * Followed in an adult or mixed CF Center of the French North-West CF Network * Not transplanted and not entered on the waiting list for transplantation * In a stable condition for at least 4 weeks * Able to understand and respect the protocol and its requirements * Who signed the consent prior to any other procedure protocol

Exclusion criteria

* Major patients under guardianship / curatorship * Patients seen in emergency situation * Pregnant patients * Dialysis patients * Patients with urolithiasis * Patients with severe exacerbation at the time of inclusion * Patients on intravenous antibiotics within 4 weeks prior to inclusion * Patient with an urinary tract infection (evaluation by dipstick at the time of inclusion

Design outcomes

Primary

MeasureTime frameDescription
Urinary Symptom Profile (USP) scoreat time of inclusionAssesses lower urinary tract symptoms (stress urinary incontinence, overactive bladder syndrome and dysuria)

Secondary

MeasureTime frameDescription
Wexner Fecal Incontinence Scaleat time of inclusionAssesses anal incontinence and its impact on quality of life
SF-Qualiveen questionnaireat time of inclusionAssesses impact of urinary disorders on quality of life
International Index of Erectile Function (IIEF5) questionnaireat time of inclusionAssesses male sexual dysfunction
Female Sexual Function Index (FSFI)at time of inclusionAssesses female sexual dysfunction
Cystic Fibrosis Questionnaire-Revised (CFQ-R)at time of inclusionAssesses quality of live related to cystic fibrosis

Other

MeasureTime frameDescription
Informations Questionnaireat time of inclusionidentification and prevalence of risk factors; impact degree of disorders on care, social and love life, sexuality

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026